Recent and anticipated novel drug approvals (4Q 2024 through 3Q 2025).
| Autor: | Rim MH; Northwestern Medicine, Chicago, IL, USA., Dean C; Northwestern Medicine, Chicago, IL, USA., Aliaj E; Northwestern Medicine, Chicago, IL, USA., Dandino M; Northwestern Medicine, Chicago, IL, USA., Tanriverdi T; Northwestern Medicine, Chicago, IL, USA., Levitsky AM; IPD Analytics, Aventura, FL, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2024 Nov 23. Date of Electronic Publication: 2024 Nov 23. |
| DOI: | 10.1093/ajhp/zxae352 |
| Abstrakt: | Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose: Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing updates on new and anticipated novel drug approvals. Summary: Selected drug approvals anticipated in the 12-month period covering the fourth quarter of 2024 through the third quarter of 2025 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from among 51 novel drugs awaiting US Food and Drug Administration approval. New drugs for severe rare diseases, cancers, autoimmune diseases, acute pain, and reversal of anticoagulation are being developed. Additionally, a new cell therapy for treatment of graft-versus-host disease joined the group of novel targeted therapies for various diseases awaiting approval. Conclusion: Novel therapies for treating rare diseases and cancers continue to strengthen the current drug pipeline. (© American Society of Health-System Pharmacists 2024. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|